Keith Bowman

1.9k total citations · 1 hit paper
16 papers, 1.4k citations indexed

About

Keith Bowman is a scholar working on Molecular Biology, Epidemiology and Small Animals. According to data from OpenAlex, Keith Bowman has authored 16 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Epidemiology and 2 papers in Small Animals. Recurrent topics in Keith Bowman's work include Advanced biosensing and bioanalysis techniques (6 papers), RNA Interference and Gene Delivery (5 papers) and Hepatitis B Virus Studies (3 papers). Keith Bowman is often cited by papers focused on Advanced biosensing and bioanalysis techniques (6 papers), RNA Interference and Gene Delivery (5 papers) and Hepatitis B Virus Studies (3 papers). Keith Bowman collaborates with scholars based in United States, United Kingdom and Switzerland. Keith Bowman's co-authors include Chandra Vargeese, Barry Polisky, Dylan Morrissey, Karin S. Blanchard, Jennifer A. Lockridge, Kristi Jensen, Shawn Zinnen, Ian MacLachlan, Lloyd B. Jeffs and Adam D. Judge and has published in prestigious journals such as Nature Biotechnology, Hepatology and Journal of Hepatology.

In The Last Decade

Keith Bowman

15 papers receiving 1.3k citations

Hit Papers

Potent and persistent in vivo anti-HBV activity of chemic... 2005 2026 2012 2019 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
    2005 908 citations Dylan Morrissey, Jennifer A. Lockridge et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith Bowman United States 10 1.2k 363 200 173 147 16 1.4k
Matthias John Germany 19 1.4k 1.1× 360 1.0× 198 1.0× 244 1.4× 218 1.5× 28 1.7k
Shuai Zhen China 17 917 0.8× 258 0.7× 180 0.9× 99 0.6× 122 0.8× 35 1.2k
Josette Svab France 17 940 0.8× 100 0.3× 99 0.5× 364 2.1× 123 0.8× 23 1.3k
Shivkumar Venkatasubrahmanyam United States 12 1.4k 1.1× 220 0.6× 110 0.6× 277 1.6× 115 0.8× 16 1.9k
Martha French United States 10 515 0.4× 119 0.3× 230 1.1× 108 0.6× 38 0.3× 13 723
Y Li China 10 330 0.3× 69 0.2× 152 0.8× 129 0.7× 72 0.5× 23 818
Guigao Lin China 17 688 0.6× 320 0.9× 135 0.7× 61 0.4× 177 1.2× 71 1.2k
Anand Kornepati United States 15 1.2k 1.0× 170 0.5× 229 1.1× 274 1.6× 245 1.7× 22 1.7k
Jørn Koch Denmark 25 1.4k 1.2× 205 0.6× 415 2.1× 53 0.3× 120 0.8× 67 1.9k
Mario Filion Canada 15 689 0.6× 43 0.1× 233 1.2× 243 1.4× 80 0.5× 31 1.2k

Countries citing papers authored by Keith Bowman

Since Specialization
Citations

This map shows the geographic impact of Keith Bowman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Bowman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Bowman more than expected).

Fields of papers citing papers by Keith Bowman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Bowman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Bowman. The network helps show where Keith Bowman may publish in the future.

Co-authorship network of co-authors of Keith Bowman

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Bowman. A scholar is included among the top collaborators of Keith Bowman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Bowman. Keith Bowman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Byrne, Michael, Vinod Vathipadiekal, Luciano H. Apponi, et al.. (2021). Stereochemistry Enhances Potency, Efficacy, and Durability of Malat1 Antisense Oligonucleotides In Vitro and In Vivo in Multiple Species. Translational Vision Science & Technology. 10(1). 23–23. 19 indexed citations
3.
Apponi, Luciano H., Naoki Iwamoto, Maria Frank-Kamenetsky, et al.. (2018). Stereochemistry enhances pharmacological properties of APOC3 antisense oligonucleotides. Journal of Hepatology. 68. S137–S137. 1 indexed citations
4.
Panzara, Michael, Carlo Rinaldi, Graham McClorey, et al.. (2017). Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD). Journal of the Neurological Sciences. 381. 277–278. 1 indexed citations
5.
Wood, Matthew J. A., Keith Bowman, David Butler, et al.. (2017). WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration. Neuromuscular Disorders. 27. S217–S217. 4 indexed citations
6.
Wilson, Stephen C., Jeremy L. Baryza, Keith Bowman, et al.. (2015). Real Time Measurement of PEG Shedding from Lipid Nanoparticles in Serum via NMR Spectroscopy. Molecular Pharmaceutics. 12(2). 386–392. 48 indexed citations
7.
Faller, Thomas, Esther van de Kerkhof, François Natt, et al.. (2014). Biodistribution and Metabolism Studies of Lipid Nanoparticle–Formulated Internally [3H]-Labeled siRNA in Mice. Drug Metabolism and Disposition. 42(3). 431–440. 43 indexed citations
8.
Saberi, Maziyar, Simon Schenk, Takeshi Imamura, et al.. (2009). Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 297(5). E1137–E1146. 62 indexed citations
9.
Morrissey, Dylan, Jennifer A. Lockridge, Karin S. Blanchard, et al.. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology. 23(8). 1002–1007. 908 indexed citations breakdown →
10.
Morrissey, Dylan, Karin S. Blanchard, Kristi Jensen, et al.. (2005). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†. Hepatology. 41(6). 1349–1356. 219 indexed citations
11.
Morrissey, Dylan, David A. Johnson, James A. McSwiggen, et al.. (2002). Characterization of nuclease‐resistant ribozymes directed against hepatitis B virus RNA*. Journal of Viral Hepatitis. 9(6). 411–418. 19 indexed citations
12.
Blikslager, Anthony T., et al.. (1995). Loop colostomy for treatment of grade-3 rectal tears in horses: seven cases (1983-1994). PubMed. 207(9). 1201–5. 10 indexed citations
13.
Haven, Michelle L., et al.. (1993). Surgical management of urolithiasis in small ruminants.. PubMed. 83(1). 47–55. 51 indexed citations
14.
Blikslager, Anthony T., Stephen Baines, & Keith Bowman. (1992). Excision of the distal sesamoid bone for treatment of infection of the digit in a heifer.. PubMed. 201(12). 1905–6. 5 indexed citations
15.
Frazier, Donita L., et al.. (1986). Increased gentamicin nephrotoxicity in normal and diseased dogs administered identical serum drug concentration profiles: increased sensitivity in subclinical renal dysfunction.. Journal of Pharmacology and Experimental Therapeutics. 239(3). 946–951. 13 indexed citations
16.
Riviere, J. E., et al.. (1985). Decreased fractional renal excretion of gentamicin in subtotal nephrectomized dogs.. Journal of Pharmacology and Experimental Therapeutics. 234(1). 90–93. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthias John Breakdown of academic impact, for papers by Shuai Zhen Breakdown of academic impact, for papers by Josette Svab Breakdown of academic impact, for papers by Shivkumar Venkatasubrahmanyam Breakdown of academic impact, for papers by Martha French Breakdown of academic impact, for papers by Y Li Breakdown of academic impact, for papers by Guigao Lin Breakdown of academic impact, for papers by Anand Kornepati Breakdown of academic impact, for papers by Jørn Koch Breakdown of academic impact, for papers by Mario Filion
Rankless by CCL
2026